Bio-Thera(SH:688177) 智通财经网·2025-09-10 08:22Core Viewpoint - Company Baiotai (688177.SH) has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for its biosimilar drug Qletli® (BAT1406, Adalimumab injection) [1] Group 1: Product Development - BAT1406 is a biosimilar of Adalimumab developed independently by the company, expressed in CHO cells as a recombinant fully human monoclonal antibody [1] - The drug works by specifically binding to TNF-α and neutralizing its biological function, blocking its interaction with cell surface TNF-α receptors, thereby inhibiting the inflammatory effects of TNF-α [1] Group 2: Market Impact - With the approval from the UK MHRA, Qletli® can now be marketed and sold in the UK, further expanding the company's overseas product offerings [1] - This approval is expected to enhance the company's international influence and may have a positive impact on its long-term operational performance [1]